Journal
BIOMARKERS IN MEDICINE
Volume 4, Issue 5, Pages 761-770Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.10.87
Keywords
biomarker; colorectal cancer; diagnosis; miRNA; prognosis; therapeutic target
Categories
Funding
- NIH/National Cancer Institute [2U54-CA118948, 3R01-CA098932, R03-CA139629]
- NATIONAL CANCER INSTITUTE [R03CA139629, U54CA118623, R01CA098932, U54CA118948] Funding Source: NIH RePORTER
Ask authors/readers for more resources
miRNAs serve as micromanagers, negatively regulating gene expression. Since altered miRNA expression is implicated in the pathobiology of various cancers, including colorectal cancers (CRCs), these molecules serve as potential therapeutic targets. Manipulation of miRNAs may offer an alternative therapy for chemo- and radio-resistant CRCs. For CRC patients, miRNA expression patterns can be used for diagnosis, and to predict prognosis and efficacy of therapy. This article describes the methodological approaches for miRNA measurement, their function in the pathobiology of CRCs and their potential clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available